Tokyo, Japan

Akio Miwa

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Misawa Homes Co., Ltd., Shin Nikkei Company, Ltd., Taisho Pharmaceutical Co., Ltd.. Active years: 1996-2004.


% Patents Active = 50.0

 

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1996-2004

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Akio Miwa: Innovator in Pharmaceuticals and Renewable Energy

Introduction

Akio Miwa is a notable inventor based in Tokyo, Japan. He has made significant contributions to the fields of pharmaceuticals and renewable energy. With a total of 2 patents, his work reflects a commitment to innovation and practical solutions.

Latest Patents

One of Miwa's latest patents is a pharmaceutical composition that includes N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and sulfobutyl ether β-cyclodextrin. This composition enhances the solubility of the active ingredient and improves its photostability. Another significant patent involves a roof panel and roof structure integrated with solar batteries. This design aims to improve water blocking between adjacent solar batteries, ensuring efficient drainage and functionality.

Career Highlights

Throughout his career, Akio Miwa has worked with prominent companies such as Taisho Pharmaceutical Co., Ltd. and Shin Nikkei Company, Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas.

Collaborations

Miwa has collaborated with notable individuals in his field, including Osamu Ishikawa and Shusei Ito. These partnerships have contributed to the advancement of his projects and patents.

Conclusion

Akio Miwa's contributions to pharmaceuticals and renewable energy demonstrate his innovative spirit and dedication to improving technology. His patents reflect a blend of scientific research and practical application, making him a significant figure in his field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…